Multiple Myeloma
Multiple Myeloma
Advertisement
Cancer Nursing Today EditorsMultiple Myeloma | September 22, 2023
Although oral chemotherapy is convenient, adherence and safety must be monitored, especially in older patients.
Read More
Dustin SamplesMultiple Myeloma | September 1, 2023
Health care providers must recognize discordances in patient-centered care beliefs and collaboratively devise care plans.
Dustin SamplesMultiple Myeloma | September 1, 2023
Researchers identified genes related to copper deficiency and explored their role in MM.
Dustin SamplesMultiple Myeloma | September 1, 2023
Steroid-induced diabetes did not affect survival, but DM diagnosis at the time of MM diagnosis led to worse outcomes.
Dustin SamplesMultiple Myeloma | September 1, 2023
Certain genetic markers predicted worse overall survival outcomes in a recent study.
Olivia ThomasMultiple Myeloma | August 9, 2023
While other symptoms did emerge, the most common was worry. Could improving other symptoms lessen worry?
Olivia ThomasMultiple Myeloma | August 9, 2023
Exercise is often recommended for patients with MM as part of a general well-being approach, but can it actually worsen QoL?
Dustin SamplesMultiple Myeloma | July 31, 2023
Using carfilzomib instead of bortezomib improved progression-free and overall survival and reduced toxicity.
Dustin SamplesMultiple Myeloma | July 31, 2023
The difference was significant, with patients who received AHSCT with residual clonal plasma cells having much lower OS.
Dustin SamplesMultiple Myeloma | July 31, 2023
Though attrition rates increased, they were lower than previously reported.
Olivia ThomasMultiple Myeloma | July 26, 2023
Four themes were identified from patient telephone interview responses that summarized the experience of living with MM.
Teresa Hagan Thomas, PhD, RNMultiple Myeloma | June 22, 2023
Patients reported higher levels of gastrointestinal, psychological, and dermatological side-effects than their providers did.
Dustin SamplesConferences | May 2, 2023
Patients who remained MRD-negative for ≥12 months had better duration of response and progression-free survival.
Dustin SamplesMultiple Myeloma | March 27, 2023
The HealthTree Foundation for Multiple Myeloma interviews Dr. Urvi Shah about IVIG.
Dustin SamplesMultiple Myeloma | March 27, 2023
Fluorescence in situ hybridization can detect genetic abnormalities that allow stratification of disease risk.
Dustin SamplesMultiple Myeloma | March 27, 2023
Only 2 patients experienced adverse events higher than grade 1 or 2, and response rates were high.
Dustin SamplesMultiple Myeloma | March 20, 2023
Toxicity- and disease-related adverse outcomes can affect the quality of life in this high-exposure population.
Dustin SamplesMultiple Myeloma | March 20, 2023
Non-Hispanic Black and Hispanic patients reported worse mental health and poorer sleep than their non-Hispanic White peers.
Dustin SamplesMultiple Myeloma | March 20, 2023
Half of all patients in a synthesized analysis developed infections, and a quarter developed grade III/IV infections.
Dustin SamplesMultiple Myeloma | March 13, 2023
Survey respondents described transportation, information, and scheduling barriers to treatment.
Advertisement
Advertisement
Advertisement